MBX Biosciences, Inc. (MBX) Q1 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning, everyone. Thanks for joining us today. We have a presentation with Microbics Biosystems, where we're going to go through their fiscal Q1 results. With me today, I have Cameron Groom, CEO, Jim Curry, CFO, Ken Hughes, COO. Before we jump into everything, I don't think we're going to work off a presentation, but just so everyone's aware, this session will contain forward-looking statements. If you'd like to know more about those, you can find them on the company's presentation on the website, which will be updated today at some point. And... The session will consist of a bit of an overview of the quarter from management, and then we'll jump into Q&A. So feel free to put any questions you have in the Q&A box or you can email them to me. And I apologize. I'm a little bit under the weather. So if I have a hack attack, my apologies in advance. I did go get tested, but it wasn't point of care. So five days later, I still don't know what I have, Cameron. Well, case in point, Debra, I hope you're feeling better soon. And maybe we'll get you into the lab and we can add to our viral seed banks. Thanks. Yeah, my bet is on RSV, but I thought I had it in December. So who knows? Anyway, one of the more important things. Cameron, do you want to kick us off with a dialogue about the quarter? Sure. Sure. Well, why don't I'll start with a bit of a financial overview and ask Jim to expand on that. And then we can talk about some of the operational achievements. I'll lead in on those and ask Ken to expand on some of those achievements. It's a pretty long list, and we could go well above the appointed time, but we'll try to keep everything concise. In short, it was an excellent quarter. We came in with revenues just over $6 million, and that is, on the surface of it, down ver...